Güerri-Fernández Robert, Villar-García Judit, Díez-Pérez Adolfo, Prieto-Alhambra Daniel
Infectious Diseases, Hospital Universitari del Mar. Parc de Salut Mar. IMIM, Barcelona, Spain.
Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Arq Bras Endocrinol Metabol. 2014 Jul;58(5):478-83. doi: 10.1590/0004-2730000003323.
With the advent of high active antiretroviral therapy there was a significant improvement on HIV subjects survival. Thus, bone changes related to HIV became an important aspect of these individuals. HIV affects bone remodeling causing bone fragility. In addition, antiretroviral therapy may also negatively affect bone metabolism. Several studies describe an increased incidence of fractures in these patients when compared with controls without the disease. The European Society of AIDS (EACS), and other societies, have included guidance on management of osteoporosis in HIV-infected patients emphasizing the identification of patients with low bone mass. Supplementation of calcium and vitamin D and the use of alendronate in these individuals should be recommended on a case base.
随着高效抗逆转录病毒疗法的出现,HIV感染者的生存率有了显著提高。因此,与HIV相关的骨骼变化成为这些患者的一个重要方面。HIV会影响骨重塑,导致骨质脆弱。此外,抗逆转录病毒疗法也可能对骨代谢产生负面影响。几项研究表明,与未患该疾病的对照组相比,这些患者骨折的发生率有所增加。欧洲艾滋病学会(EACS)和其他学会已纳入了关于HIV感染患者骨质疏松管理的指南,强调对低骨量患者的识别。应根据具体情况建议这些患者补充钙和维生素D,并使用阿仑膦酸盐。